Mini-Oral
T-DXd
SABCS 2025 | December 9 - 12, 2025
Breast Cancer
Additional efficacy and safety from the DESTINY-Breast05 study of trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients with high-risk human epidermal growth factor receptor 2–positive (HER2+) primary early breast cancer with residual invasive disease after neoadjuvant therapy
Sibylle Loibl
Oral
T-DXd
JBCS 2025 | July 10-12, 2025
Breast Cancer
AI-based analyses of trastuzumab deruxtecan-related interstitial lung disease/pneumonitis: TILD-A
Naoya Tanabe
Poster
T-DXd
AACR 2025 | April 25-29, 2025
Breast Cancer
Baseline serum protein analysis of patients with interstitial lung disease/pneumonitis (ILD) in 3 trastuzumab deruxtecan (T-DXd) trials: DESTINY-Breast01, DESTINY-Breast04, and DESTINY-Lung01
Zenta Tsuchihashi
Poster
T-DXd
ESMO Breast 2025 | May 14-17, 2025
Breast Cancer
Chemotherapy outcomes in human epidermal growth factor receptor 2 (HER2)‑low, hormone receptor positive (HR+) metastatic breast cancer (mBC): Insights from the French multicenter ESME database
William Jacot
Oral
Dato-DXd
ESMO 2025 | October 17-21, 2025
Breast Cancer
Datopotamab deruxtecan (Dato-DXd) in combination with durvalumab as
first-line treatment for unresectable locally advanced/metastatic triple-negative breast cancer: Results from arms 7 and 8 of the phase 1b/2 BEGONIA study
Peter Schmid
Poster
T-DXd
SABCS 2025 | December 9 - 12, 2025
Breast Cancer
DESTINY-Breast Respond HER2-low Europe:
Description of first enrolled patients in the
non-interventional study of T-DXd in HER2-low
metastatic breast cancer
Valentina Guarneri
Mini-Oral
T-DXd
ESMO Breast 2025 | May 14-17, 2025
Breast Cancer
DESTINY-Breast06 (DB-06) post-hoc analysis by physician’s choice of chemotherapy (TPC): Efficacy and safety of trastuzumab deruxtecan (T-DXd) vs TPC in hormone receptor–positive (HR+), HER2-low or -ultralow metastatic breast cancer (mBC)
Carlos H. Barrios
Mini-Oral
T-DXd
SABCS 2025 | December 9 - 12, 2025
Breast Cancer
DESTINY-Breast11 safety: Neoadjuvant trastuzumab deruxtecan (T-DXd) alone or followed by paclitaxel + trastuzumab + pertuzumab (THP) vs dose-dense doxorubicin + cyclophosphamide followed by THP (ddAC-THP) in high-risk, HER2+ early-stage breast cancer
Giuseppe Curigliano
Oral
T-DXd
ESMO 2025 | October 17-21, 2025
Breast Cancer
DESTINY-Breast11: Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel + trastuzumab + pertuzumab vs ddAC-THP for high-risk HER2+ early breast cancer
Nadia Harbeck
Mini-Oral
T-DXd
ESMO Asia 2025 | December 5-7, 2025
Breast Cancer
DESTINY-Breast11: Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel + trastuzumab + pertuzumab vs ddAC-THP for high-risk HER2+ early breast cancer
Nadia Harbeck
